We have a diverse pipeline designed to make a meaningful difference for patients
Our growing development pipeline of innovative new therapies is driven by the flexibility of our TransCon® technologies and our aim to improve patients' lives. We have multiple prodrug therapies in development. Each candidate is unique and designed to be a best-in-class therapy.
Endocrinology Rare Diseases1
Phase 1
Phase 2
Phase 3
TransCon hGH
Pediatric Growth Hormone Deficiency
(Greater China)1
(Greater China)1
Phase 3
Pediatric Growth Hormone Deficiency
(Japan)2
(Japan)2
Phase 3
Adult Growth Hormone Deficiency
(Global)3
(Global)3
Phase 3
TransCon PTH
Adult Hypoparathyroidism
(North America & Europe)4
(North America & Europe)4
Phase 3
Adult Hypoparathyroidism
(Greater China)1
(Greater China)1
Phase 3
Adult Hypoparathyroidism
(Japan)5
(Japan)5
Phase 3
TransCon CNP
Pediatric Achondroplasia
(North America, Europe, Oceania)6
(North America, Europe, Oceania)6
Phase 2
Pediatric Achondroplasia
(Greater China)1
(Greater China)1
Phase 2
Oncology4
Phase 1
Phase 2
Phase 3
TransCon TLR7/8 Agonist
Monotherapy7
Phase 1
Combination Therapy7
Phase 1
TransCon IL-2 β/γ
Monotherapy8
Phase 1
Combination Therapy8
Phase 1
1 In development in Greater China through strategic investments in VISEN Pharmaceuticals
2 Japanese riGHt Trial
3 Global foresigGHt Trial
4 North American and European PaTHway Trial
5 Japanese PaTHway Japan Trial
6 North America, Europe, and Oceania AComplisH Trial
7 transcendIT 101 Trial
8 IL-βelieγe Trial
Explore
